CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma
CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma
复制标题
DOI：
10.1309/ajcp61tlmxlsljys
复制
发表时间：
2014-03-01
影响因子：
3.5
通讯作者：
Kreisel, Friederike
中科院分区：
文献类型：
--
作者：
Klein, Jonathan L.;Nguyen, TuDung T.;Kreisel, Friederike
目的：近年来，研究越来越多地集中在经典霍奇金淋巴瘤（CHL）的微环境作为治疗结果的预测因子。本研究的重点是评估观察者间的再现性解释巨噬细胞相关免疫组织化学（IHC）的CD68和CD163在一个回顾性队列的88例CHL.Methods：染色结果与临床结果在所有患者和那些具有高国际预后评分（IFS）。5名血液病理学家解释IHC的组内相关性（ICC），CD163（0.70）强于CD68（0.50）。使用25%平均巨噬细胞反应性的截止值并包括所有患者，仅观察到CD 163（P = .0006）而非CD 68（P = .414）的总生存期（OS）存在统计学显著差异。平均CD 163反应性≥ 25%的患者的中位OS为71个月，而反应性低于25%的患者的中位OS为101个月。在多变量分析中，CD163保持统计学显著性。在晚期CHL与高IPS患者，OS也显着恶化的平均CD163反应性为25%或higher.Conclusions：我们的研究证实了以前的报告的肿瘤浸润性巨噬细胞在CHL的预后作用，但只有CD163。尽管大多数文献支持巨噬细胞免疫组化作为临床结果预测因子的作用越来越大，但成功的临床转化将需要标准化的方法和报告系统。
Objectives: In recent years, research has increasingly focused on the microenvironment of classical Hodgkin lymphoma (CHL) as a predictor of treatment outcome. The focus of this study was to assess the interobserver reproducibility in interpreting macrophage-associated immunohistochemistry (IHC) for CD68 and CD163 in a retrospective cohort of 88 patients with CHL.Methods: Staining results were correlated with clinical outcome in all patients and those with a high international prognostic score (IFS).Results: The intraclass correlation (ICC) for the five hematopathologists interpreting the IHC was stronger for CD163 (0.70) than for CD68 (0.50). Using a cutoff of 25% mean macrophage reactivity and including all patients, a statistically significant difference in overall survival (OS) was seen only for CD 163 (P = .0006) and not for CD68 (P = .414). Patients with a mean CD 163 reactivity of 25% or more had a median OS of 71 months vs 101 months for patients with less than 25% reactivity. CD163 retained statistical significance in multivariate analysis. In patients with advanced-stage CHL with high IPS, OS was also significantly worse for those with a mean CD163 reactivity of 25% or higher.Conclusions: Our study confirms previous reports of a prognostic role of tumor-infiltrating macrophages in CHL, but only for CD163. Although most of the literature supports an increasing role of macrophage IHC as a predictor of clinical outcome, successful clinical translation will require a standardized method and reporting system.